A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2014
At a glance
- Drugs Vorsetuzumab mafodotin (Primary)
- Indications Non-Hodgkin's lymphoma; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 23 Jul 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 02 Apr 2012 Actual patient number changed from 113 to 58 as reported by ClinicalTrials.gov.
- 08 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.